Prognostic Value of Inflammatory Indices in Papillary Gastric Carcinoma with Different Proportions of Papillary Components

炎症指标在不同乳头状成分比例的乳头状胃癌中的预后价值

阅读:1

Abstract

PURPOSE: To evaluate the prognostic significance of peripheral inflammatory indices in patients with advantage papillary gastric carcinoma (APGC) and non-advantage papillary gastric carcinoma (NAPGC). METHODS: The study retrospectively analyzed 270 patients who underwent radical surgery. Patients were stratified into APGC (n=133) and NAPGC (n=137) cohorts based on papillary component proportion (≥50% papillary histology for APGC, <50% for NAPGC). Receiver operating characteristic curve analysis was performed to assess the sensitivity of inflammatory indices for prognostic prediction. Overall survival was analyzed using Kaplan‒Meier survival and Log rank tests. The relationship between inflammatory indicators and clinicopathological characteristics was examined. Independent prognostic risk factors were identified using the Cox regression model and integrated into a nomogram, with calibration plots and decision curves used to evaluate predictive performance. RESULTS: Compared to NAPGC patients, APGC patients demonstrated higher pT stage and carcinoembryonic antigen (CEA) levels, with poorer survival outcomes. Stage III APGC patients showed higher peripheral blood neutrophil ratios than NAPGC patients. For APGC, neutrophil-to-lymphocyte ratio (NLR) and CEA were identified as independent prognostic factors, while for NAPGC, systemic immune-inflammatory index (SII), age, and pN stage were determined to be independent prognostic factors. CONCLUSION: Significant differences exist in clinicopathological characteristics, peripheral blood inflammatory indices, and prognosis between APGC and NAPGC patients. The nomogram incorporating inflammatory indices NLR and SII effectively predicts prognosis in both APGC and NAPGC patients.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。